Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes

CHIA-TER CHAOJUI WANGWu, Hon-YenHon-YenWuKUO-LIONG CHIENKUAN-YU HUNG2022-10-282022-10-282017-08-081949-2553https://scholars.lib.ntu.edu.tw/handle/123456789/624063Dipeptidyl peptidase 4 inhibitor (DPP4i) use potentially slows the progression of diabetic kidney disease, but its effects on the risk of acute kidney injury (AKI) are unclear. We aimed to assess the association between DPP4i use and incident AKI episodes from a nationally representative cohort in Taiwan.enacute kidney injury; chronic kidney disease; diabetes mellitus; dialysis-requiring acute kidney injury; dipeptidyl peptidase 4 inhibitor[SDGs]SDG3Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetesjournal article10.18632/oncotarget.18081288817912-s2.0-85030093299WOS:000407124100084https://api.elsevier.com/content/abstract/scopus_id/85030093299